Royal Philips
Philips introduces integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3 to improve workflow and patient focus during image-guided procedures at ACC.21
Philips introduces integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3 to improve workflow and patient focus during image-guided procedures at ACC.21
May 14, 2021
Continuous monitoring provides informed, timely clinical decision making and comprehensive, gap-free patient records in the cath lab and beyond
Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the integration of its
Patient Monitor IntelliVue X3, providing advanced hemodynamic (blood flow) measurements at the tableside in the cath lab and continuous monitoring of key vital signs throughout the patient journey [1]. The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided
Philips introduces integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3 to improve workflow and patient focus during image-guided procedures at ACC.21
May 14, 2021 04:00 ET | Source: Royal Philips Royal Philips
May 14, 2021
Continuous monitoring provides informed, timely clinical decision making and comprehensive, gap-free patient records in the cath lab and beyond
Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the integration of its
Patient Monitor IntelliVue X3, providing advanced hemodynamic (blood flow) measurements at the tableside in the cath lab and continuous monitoring of key vital signs throughout the patient journey [1]. The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely
email article
Is angiotensin receptor-neprilysin inhibition (ARNI) doomed as a therapy for heart attack survivors with left ventricular dysfunction? Or could there be some redeeming data to suggest otherwise?
The answer is expected from the PARADISE-MI study presentation to be held during the opening late-breaking trial session at this year s virtual American College of Cardiology (ACC) meeting.
PARADISE-MI is the first head-to-head comparison of ARNI versus angiotensin-converting enzyme (ACE) inhibitor therapy after myocardial infarction (MI) in patients who have reduced left ventricular ejection fraction. Investigators randomized more than 5,600 patients to sacubitril/valsartan (Entresto) or ramipril, their primary endpoint being cardiovascular death, heart failure hospitalization, or development of symptomatic heart failure.
New Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients
New findings from an American College of Cardiology’s survey revealed more than half of cardiologists believe patient preparation may lead to better quality discussions around treatment options for heart valve disease . Results from the ACC CardioSurve panelist survey, sponsored by Medtronic and conducted by the American College of Cardiology, garnered responses from more than 150 cardiologists around key factors …
– New findings from an American College of Cardiology’s (ACC) survey revealed more than half of cardiologists (57%) believe patient preparation may lead to better quality discussions around treatment options for heart valve disease (HVD). Results from the ACC CardioSurve panelist survey, sponsored by Medtronic (NYSE: MDT), and conducted by the American College of Cardiology, garnered responses from more than 150 cardiologists around key fa
ACC Survey: 44% of Cardiologists Report a Hostile Work Environment medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.